Themesothelioma News
Friday, May 24, 2019
In CF Children, Kalydeco Benefits Maintained Long-term in Phase 3 Trial
In CF Children, Kalydeco Benefits Maintained Long-term in Phase 3 Trial
Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows
MAY 24, 2019
BY
PATRICIA INACIO, PHD
IN
CYSTIC FIBROSIS
,
NEWS
.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment